HARMONi-7

SMT112-3007: A Randomized Double-Blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-Line Treatment of metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression